EQS-News

CRMI: Bio-Engineered Cornea 'ACORNEA' Exhibits at 28th Annual Meeting of European Eye Bank Association

EQS-News / 25/01/2016 / 09:42 UTC+8

[For Immediate Release]

China Regenerative Medicine International Limited
(Stock Code: 8158.HK)

Bio-Engineered Cornea "ACORNEA" Exhibits at 28th Annual Meeting of European
Eye Bank Association

[25 January 2016] (Hong Kong) - China Regenerative Medicine International
Limited ("CRMI" or the "Company," stock code: 8158.HK, together with its
subsidiaries, collectively the "Group") is pleased to announce that the
world's first bio-engineered cornea "Acornea" was exhibited at the 28th
Annual Meeting of the European Eye Bank Association ("EEBA") in Aarhus,
Denmark on the 22 January and has attracted much attention from experts all
over the world.

To date, 27 meetings of the EEBA have been successfully hosted and this
year, it attracted over 200 corneal surgeons, researchers and technicians
to exchange knowledge and technical skills and establish standard practices
for the treatment of eye diseases. This year's meeting focused on current
state-of-the-art eye banking techniques and future strategies to optimize
eye banking skills. The purpose of these meetings is to exchange
information and ideas, to promote procurement and supply of human eye
tissue for therapeutic purposes, to improve and adapt storage methods, and
to encourage the implementation of standard operating procedures. At the
same time, this is also one of the world's most influential cornea and eye
banking professional academic conferences.

In the EEBA annual meeting, Dr Zhengkang Shao, CEO of CRMI, delivered a
speech on 'China's self-developed world's first bio-engineered cornea
"Acornea" is regulatory approved and commercialised. It is not only serving
Chinese patients but also patients all over the world.' He emphasized that
effective technologies, safe development and innovative products can narrow
the gap between cornea donation levels and demand. "Acornea" will
eventually help patients to gain better quality of life as well as enhance
the collaboration between China and European eye banks. In the future, CRMI
will continue to put patient's well-being ahead of all else, and strive to
meet patient demand in a safe and effective manner.

According to the World Health Organisation, diseases affecting the cornea
are a major cause of blindness worldwide, second only to cataracts in
overall importance. Existing treatments for corneal blindness include
transplantation of donated or artificial cornea. In Asia, there is an
increasing number of patients with corneal diseases each year while cornea
donations are in short supply. Artificial cornea fabricated from synthetic